Kazia Therapeutics (Kazia Therapeutics) Common Stock

: $65.40 Mil (As of Jun. 2023)

View and export this data going back to 1999. Start your Free Trial

Kazia Therapeutics's quarterly common stock increased from Jun. 2022 ($59.37 Mil) to Dec. 2022 ($60.96 Mil) and increased from Dec. 2022 ($60.96 Mil) to Jun. 2023 ($65.40 Mil).

Kazia Therapeutics's annual common stock declined from Jun. 2021 ($61.38 Mil) to Jun. 2022 ($59.37 Mil) but then increased from Jun. 2022 ($59.37 Mil) to Jun. 2023 ($65.40 Mil).

Kazia Therapeutics Common Stock Historical Data

The historical data trend for Kazia Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

25.45

33.67

61.38

59.37

65.40

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															61.38	57.44	59.37	60.96	65.40

Kazia Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204